Related Experiment Video
Updated: Apr 3, 2026
Retinal Pathophysiological Evaluation in a Rat Model
Published on: May 6, 2022
Role of endocannabinoids in the progression of diabetic retinopathy
Tapan Behl1, Ishneet Kaur2, Anita Kotwani1
1Department of Pharmacology, Vallabhbhai Patel Chest Institute, University of Delhi, Delhi, India.
Abstract:
In the past decades, the role of numerous factors in the pathophysiology of diabetic retinopathy has been explored, following which marked progress has been made in developing several novel therapeutic options, such as anti-vascular endothelial growth factor, anti-tumor necrosis factor-alpha and various other anti-inflammatory and anti-angiogenic agents, for the treatment of diabetic retinopathy. However, the involvement of endocannabinoid system in its pathogenesis has not been much explored. This review aims at unveiling every aspect of association of the endocannabinoid system and its interactions with various physiological and pathological pathways to induce disease progression. The various alterations induced by endocannabinoids, such as anandamide and 2-arachidonylglycerol, in retina during hyperglycaemia clearly demonstrate and verify their involvement in aggravating the pathological conditions, hence leading to the progression of diabetic retinopathy. Exploring this involvement furthermore, in greater depths, might be beneficial in acknowledging and understanding the hidden aspects of the pathogenesis of this complication even better and might provide a therapeutically beneficial alternative target to combat and restrict its progression amongst diabetic patients.
Insights
The endocannabinoid system plays a role in diabetic retinopathy progression. Further research into this system may reveal new therapeutic targets for managing this diabetes complication.
Area of Science:
- Ophthalmology
- Endocrinology
- Pharmacology
Background:
- Diabetic retinopathy (DR) is a major microvascular complication of diabetes.
- Current treatments for DR include anti-vascular endothelial growth factor (anti-VEGF) and anti-inflammatory agents.
- The role of the endocannabinoid system (ECS) in DR pathogenesis remains underexplored.
Purpose of the Study:
- To review the association between the endocannabinoid system and diabetic retinopathy.
- To explore the interactions of the ECS with physiological and pathological pathways in DR.
- To identify the ECS as a potential therapeutic target for DR.
Main Methods:
- Literature review of studies investigating the ECS in the context of diabetic retinopathy.
- Analysis of the role of endocannabinoids, such as anandamide and 2-arachidonylglycerol, in retinal pathophysiology during hyperglycemia.
- Examination of existing therapeutic strategies for DR and their limitations.
Main Results:
- Hyperglycemia induces alterations in endocannabinoid levels within the retina.
- These alterations are linked to the exacerbation of pathological conditions in DR.
- Endocannabinoids contribute to the progression of diabetic retinopathy.
Conclusions:
- The endocannabinoid system is implicated in the pathogenesis of diabetic retinopathy.
- Targeting the ECS may offer a novel therapeutic strategy for managing DR.
- Further investigation into the ECS could uncover deeper insights into DR mechanisms.
